Ropack Inc. has purchased two pharmaceutical facilities in Long Island, NY, significantly expanding its capabilities, which will now include R&D, formulation, lab analysis and commercial and clinical manufacturing.
 
The buildings, formerly operated by Forest Laboratories, total 213,700 sq.-ft. Activities in the U.S.will be managed through Ropack USA Inc. Ropack Inc. and Ropack USA Inc. will now be known as Ropack Pharma Solutions.
 
“It has been a longstanding goal to broaden our service offerings,” said Yves Massicotte, president and chief executive officer. “To establish a presence in the U.S. at the same time makes this acquisition ideal.” 
 
“The purchase of these two state-of-the-art pharmaceutical facilities on Long Island will enable Ropack Pharma Solutions to provide its current and future customers with comprehensive solid oral dosage development, manufacturing and packaging solutions,” added Paul Dupont, vice president of marketing and business development. “This acquisition will add considerable capacity and key technologies to support projects from formulation development through commercialization.”
 
Ropack, celebrating its 40th anniversary in 2016, operates four facilities in Montreal, Canada, for the packaging of solid oral dosage in bottles, flip-top vials, blister packs, stick-packs and sachets.